What drove the pre-market move in 0QF.F stock today?

The pre-market rise to **€37.13** followed a Q4 revenue beat (€678.00 million) and a narrower GAAP loss, offset by an FDA refusal to review Moderna’s mRNA flu shot application.

What are the key valuation metrics for 0QF.F stock?

Key metrics include market cap **€12.90B**, EPS **-€6.78**, reported PE **-4.87**, price-to-sales **7.75**, and cash per share **€11.55**, reflecting a cash-rich but loss-making biotech profile.

How does Meyka AI view 0QF.F stock near term?

Meyka AI rates 0QF.F **64.90/100 (B, HOLD)** and projects a quarterly model target of **€47.85** (+28.87%) and monthly **€32.95** (-11.26%). Forecasts are model-based and not guarantees.

Which catalysts should investors monitor for 0QF.F stock?

Watch regulatory news on the mRNA flu shot, U.S. vaccine order flow, partnership updates, quarterly guidance, and cash conversion improvements tied to receivables and inventory.

DE Stocks

Pre-market Feb 14, 2026: 0QF.F Moderna, Inc. (XETRA) posts Q4 beat vs FDA setback: what to watch next

ByDanny Kontos February 14, 2026February 14, 2026

Pre-market on 14 Feb 2026, 0QF.F stock trades at €37.13, up 14.74%, after Moderna reported a fourth-quarter revenue beat and a narrower GAAP loss. The print showed Q4 revenue €678.00 million and GAAP EPS of -€2.11, while management reaffirmed a 10.00% revenue growth target for 2026. The market is parsing the beat against an FDA refusal to review Moderna’s mRNA flu shot. We use 0QF.F stock as our earnings spotlight to link results, valuation, and near-term catalysts for XETRA traders and Europe-based investors.